Differences in skeletal muscle loss caused by cytotoxic chemotherapy and molecular targeted therapy in patients with advanced non‐small cell lung cancer

BACKGROUND: Recent studies have revealed a reduction in the skeletal muscle area in patients with advanced non‐small cell lung cancer (NSCLC) after chemotherapy. EGFR and ALK tyrosine kinase inhibitor (TKI)‐based therapies are less cytotoxic than chemotherapy, but differences in skeletal muscle mass...

Descripción completa

Detalles Bibliográficos
Autores principales: Kakinuma, Kazutaka, Tsuruoka, Hazime, Morikawa, Kei, Furuya, Naoki, Inoue, Takeo, Miyazawa, Teruomi, Mineshita, Masamichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5754304/
https://www.ncbi.nlm.nih.gov/pubmed/29067769
http://dx.doi.org/10.1111/1759-7714.12545

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5754304/
https://www.ncbi.nlm.nih.gov/pubmed/29067769
http://dx.doi.org/10.1111/1759-7714.12545

Ejemplares similares